OC
BEAT

Oppenheimer & Co’s BioTelemetry, Inc. BEAT Stock Holding History

Oppenheimer & Co’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,990
Closed -$370K – 1377
2019
Q4 		$370K Buy
+7,990
New +$346K 0.01% 951

Other funds holding BEAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Oppenheimer & Co's BEAT Position: Q1 2020 in Review

Oppenheimer & Co sold out of BioTelemetry, Inc. (BEAT) in Q1 2020, closing a stake of 7,990 shares — an estimated $370K sold.

Oppenheimer & Co first reported a position in BEAT in Q4 2019 and held it in 1 quarter. The position peaked at $370K in Q4 2019. 209 funds tracked by Wall St. Rank hold BEAT as of Q1 2020.

  • Oppenheimer & Co reported no remaining BioTelemetry, Inc. position as of Q1 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 7,990 BioTelemetry, Inc. shares in Q1 2020, an estimated $370K.
  • Oppenheimer & Co first reported a position in BioTelemetry, Inc. in Q4 2019 and held it in 1 quarter.
  • Oppenheimer & Co's BioTelemetry, Inc. position peaked at $370K in Q4 2019.
  • 209 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2020.

Based on Oppenheimer & Co's 13F filing for Q1 2020, filed 8 May 2020.